Neurotransmitter Metabolism Disorders and Clinical Applications

Disorders of neurotransmitter metabolism encompass a range of inherited and acquired conditions characterised by disrupted synthesis, degradation or recycling of key signalling molecules such as dopamine, serotonin and norepinephrine. These conditions often stem from genetic variants affecting enzymes (for example tyrosine hydroxylase or aromatic amino acid decarboxylase) or their essential cofactors (notably tetrahydrobiopterin). Clinically, patients present with movement disorders, autonomic dysregulation, cognitive and developmental delay, and neuropsychiatric symptoms. Advances in biochemical diagnostics—including cerebrospinal fluid and blood biomarker profiling—have enabled earlier detection, while treatment strategies now integrate precursor and cofactor supplementation, enzyme inhibition, and emerging gene‐based therapies. Preclinical models using induced pluripotent stem cells and genetically modified animals have defined pathogenic mechanisms, identified critical therapeutic windows for pharmacological intervention and laid the groundwork for personalised management. Ongoing developments in analytical chemistry and deep phenotyping are refining diagnostic accuracy, harmonising clinical guidelines and expanding applications in drug discovery and precision medicine.

Research from Nature Portfolio

Recent studies have elucidated the role of a specific co-chaperone in stabilising aromatic amino acid hydroxylases. Loss of this factor in animal models induces hyperphenylalaninemia and central serotonin deficiency, highlighting new mechanistic links between enzyme homeostasis and neurotransmitter balance and suggesting a potential target for therapeutic modulation. Complementary work using a registry-based deep phenotyping approach has mapped the expanding clinical spectrum of inherited biogenic amine disorders, revealed factors that shorten diagnostic delay and informed the development of updated clinical algorithms that improve time to treatment and patient outcomes.

Neurotransmitter Metabolism Disorders and Clinical Applications publication trend

The graph below shows the total number of articles in neurotransmitter metabolism disorders and clinical applications across all publications each year (not limited to Nature Index journals).

Technical terms

Aromatic amino acid hydroxylase: Enzyme family that catalyses the rate-limiting hydroxylation of aromatic amino acids in monoamine neurotransmitter biosynthesis.

Tetrahydrobiopterin (BH4): Essential enzymatic cofactor required for phenylalanine, tyrosine and tryptophan hydroxylation in neurotransmitter synthesis.

DNAJC12: Co-chaperone protein that stabilises aromatic amino acid hydroxylases and regulates both neurotransmitter production and phenylalanine degradation.

Hyperphenylalaninemia: Elevated phenylalanine levels in blood or cerebrospinal fluid due to impaired phenylalanine hydroxylase activity, risking neurotoxicity if untreated.

iPSC (induced pluripotent stem cell): Somatic cell reprogrammed to a pluripotent state, capable of differentiating into disease-relevant neuronal lineages for mechanistic studies and drug screening.

References

1. iPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation. EMBO Molecular Medicine (2023).
2. Tetrahydrobiopterin: Beyond Its Traditional Role as a Cofactor. Antioxidants (2023).
3. Hyperphenylalaninemia and serotonin deficiency in Dnajc12-deficient mice. Communications Biology (2024).
4. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nature Communications (2021).
5. Analysis of Catecholamines and Pterins in Inborn Errors of Monoamine Neurotransmitter Metabolism—From Past to Future. Cells (2019).